Rebecca Chambers has served as member of our board of directors since June 2021. Since July 2021, Ms. Chambers has served as the Chief Financial Officer and Executive Vice President of Veracyte, Inc., a global genomic diagnostics company. From June 2019 to July 2021, Ms. Chambers served as the Chief Financial Officer of Outset Medical, Inc., a medical technology company pioneering a novel technology to reduce the cost and complexity of dialysis. Prior to that, she was at Illumina, Inc., a genetic tools company, where she served in a number of roles: as the Vice President, Financial Planning and Analysis from July 2017 to May 2019, as Vice President, Investor Relations and Treasury from April 2015 to June 2017, and as Senior Director, Investor Relations from October 2012 to April 2015. Previously, Ms. Chambers served as Head of Investor Relations and Corporate Communications at Myriad Genetics, a molecular diagnostic company, from January 2011 to October 2012, and in various roles in investor relations at Life Technologies, a biotechnology company, from May 2009 to December 2010. She also previously held positions with Bank of America, a financial services company, and Millennium Pharmaceuticals, a biopharmaceutical company that was acquired by Takeda Pharmaceuticals Co. Ms. Chambers holds a B.S. from John Carroll University and an M.B.A. from The S.C. Johnson Graduate School of Management, Cornell University.
What is Rebecca Chambers' net worth?
The estimated net worth of Rebecca Chambers is at least $6.32 million as of December 3rd, 2024. Ms. Chambers owns 114,037 shares of Inari Medical stock worth more than $6,323,352 as of December 21st. This net worth estimate does not reflect any other assets that Ms. Chambers may own. Learn More about Rebecca Chambers' net worth.
How do I contact Rebecca Chambers?
Has Rebecca Chambers been buying or selling shares of Inari Medical?
Rebecca Chambers has not been actively trading shares of Inari Medical during the past quarter. Most recently, Rebecca Chambers sold 260 shares of the business's stock in a transaction on Friday, June 21st. The shares were sold at an average price of $45.99, for a transaction totalling $11,957.40. Following the completion of the sale, the director now directly owns 9,684 shares of the company's stock, valued at $445,367.16. Learn More on Rebecca Chambers' trading history.
Who are Inari Medical's active insiders?
Are insiders buying or selling shares of Inari Medical?
In the last year, insiders at the sold shares 26 times. They sold a total of 562,744 shares worth more than $27,798,968.16. The most recent insider tranaction occured on December, 20th when CEO Andrew Hykes sold 3,000 shares worth more than $165,870.00. Insiders at Inari Medical own 10.6% of the company.
Learn More about insider trades at Inari Medical. Information on this page was last updated on 12/20/2024.
